ZYNE Zynerba Pharmaceuticals, Inc. Stock Quote

ZYNE [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	0.10%	Shs Outstand	40.09M	Perf Week	-4.76%
Market Cap	148.79M	Forward P/E	-	EPS next Y	-1.07	Insider Trans	0.00%	Shs Float	39.13M	Perf Month	-2.96%
Income	-38.10M	PEG	-	EPS next Q	-0.33	Inst Own	33.60%	Short Float	6.09%	Perf Quarter	-13.25%
Sales	-	P/S	-	EPS this Y	-26.90%	Inst Trans	-14.93%	Short Ratio	1.34	Perf Half Y	-36.62%
Book/sh	1.96	P/B	1.84	EPS next Y	-9.30%	ROA	-41.10%	Target Price	7.63	Perf Year	-21.40%
Cash/sh	1.83	P/C	1.97	EPS next 5Y	-	ROE	-47.30%	52W Range	3.15 - 9.00	Perf YTD	9.09%
Dividend	-	P/FCF	-	EPS past 5Y	7.60%	ROI	-	52W High	-59.89%	Beta	2.28
Dividend %	-	Quick Ratio	8.10	Sales past 5Y	-	Gross Margin	-	52W Low	14.60%	ATR	0.20
Employees	26	Current Ratio	8.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.34	Volatility	5.91% 5.31%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	14.70%	Profit Margin	-	Rel Volume	0.69	Prev Close	3.60
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.77M	Price	3.61
Recom	2.00	SMA20	-8.13%	SMA50	-10.83%	SMA200	-20.56%	Volume	688,907	Change	0.28%

Dec-21-20

Reiterated

H.C. Wainwright

Buy

$12 → $9

Jul-01-20

Downgrade

Needham

Buy → Hold

Dec-31-19

Resumed

ROTH Capital

Buy

$12

Oct-21-19

Initiated

Needham

Buy

$18

Apr-22-19

Resumed

Canaccord Genuity

Buy

Feb-01-18

Resumed

H.C. Wainwright

Buy

$23

Jan-29-18

Initiated

Ladenburg Thalmann

Buy

$25.50

Jan-26-18

Initiated

Seaport Global Securities

Buy

$16

Oct-02-17

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$4 → $17

Sep-29-17

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-15-17

Upgrade

ROTH Capital

Neutral → Buy

Aug-15-17

Downgrade

Oppenheimer

Outperform → Perform

Aug-15-17

Downgrade

Jefferies

Buy → Hold

Aug-08-17

Downgrade

ROTH Capital

Buy → Neutral

Aug-08-17

Downgrade

H.C. Wainwright

Buy → Neutral

Aug-07-17

Downgrade

Piper Jaffray

Overweight → Neutral

Aug-07-17

Downgrade

Maxim Group

Buy → Hold

Aug-07-17

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$28 → $4

Mar-28-17

Reiterated

H.C. Wainwright

Buy

$22 → $30

Feb-24-17

Initiated

Maxim Group

Buy

$32

Nov-22-21 07:00AM	Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel GlobeNewswire
Nov-15-21 07:00AM	Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
Oct-21-21 07:00AM	Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October GlobeNewswire
Oct-19-21 04:15PM	Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire
Oct-08-21 07:30AM	Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition GlobeNewswire
Sep-20-21 07:00AM	Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-13-21 07:00AM	Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome GlobeNewswire
Sep-09-21 11:06AM	Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children Benzinga +5.32%
07:00AM	Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire
Sep-07-21 07:00AM	Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open GlobeNewswire
Sep-02-21 07:30AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire +6.34%
07:00AM	Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire
Aug-09-21 07:00AM	Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
Aug-04-21 07:30AM	Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Aug-02-21 01:31PM	10 Best CBD Stocks to Invest In Insider Monkey
Jul-07-21 07:30AM	Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference GlobeNewswire
Jun-30-21 07:00AM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire
Jun-29-21 09:01AM	Should I Buy Zynerba Pharmaceuticals Inc (ZYNE)? Insider Monkey
Jun-11-21 02:44PM	Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies Benzinga
12:30PM	Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting GlobeNewswire
Jun-09-21 04:05PM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire
Jun-07-21 08:00AM	Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. ZYNE GlobeNewswire
Jun-04-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting GlobeNewswire
Jun-03-21 10:00AM	Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire
May-27-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire
May-26-21 07:30AM	Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +5.45%
07:00AM	Notice of Settlement of Derivative Actions GlobeNewswire
May-17-21 08:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference GlobeNewswire
May-12-21 06:45AM	Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
May-06-21 07:53AM	Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside SmarterAnalyst -8.03%
May-05-21 04:05PM	Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel in Fragile X Syndrome GlobeNewswire
Apr-29-21 02:00PM	Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting GlobeNewswire
Apr-15-21 07:30AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting GlobeNewswire -6.93%
Apr-06-21 07:30AM	Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 12:15PM	Inside the Top-Performing ETFs of Q1 Zacks
Mar-28-21 08:15AM	Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel PR Newswire
Mar-12-21 05:22AM	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? Simply Wall St.
Mar-10-21 06:45AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights GlobeNewswire
Mar-05-21 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-04-21 08:00AM	Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference GlobeNewswire -9.31%
Feb-26-21 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
Feb-11-21 11:29AM	GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players Market Exclusive -30.25%
Feb-03-21 04:25PM	GW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover Deal Investor's Business Daily +27.39%
Jan-04-21 07:30AM	Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire
Dec-23-20 05:30AM	Here's What We Think About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Pay Simply Wall St.
Dec-17-20 08:10AM	The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga -16.51%
06:30AM	Zynerba Pharmaceuticals Provides Regulatory Update on Zygel in Fragile X Syndrome GlobeNewswire
Dec-09-20 03:49PM	Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire
Dec-08-20 06:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Dec-07-20 12:00PM	The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors Business Wire
Dec-04-20 11:30AM	Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Dec-03-20 09:27PM	Is Zynerba Pharmaceuticals (ZYNE) A Good Stock To Buy Now? Insider Monkey
Nov-23-20 11:45AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Nov-09-20 11:20AM	Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results Benzinga
06:45AM	Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights GlobeNewswire
Oct-16-20 11:01AM	Canaccord Predicts Over 100% Rally for These 3 Strong Buy Stocks TipRanks
02:55AM	Zynerba Up 6% As Zygel Shows Promise In Autism Trial SmarterAnalyst
Oct-15-20 03:06PM	Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting GlobeNewswire +6.44%
03:05PM	New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting GlobeNewswire
Oct-08-20 08:32AM	Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting GlobeNewswire
08:30AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting GlobeNewswire
Sep-23-20 02:37PM	We're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Rate Simply Wall St. -7.14%
Sep-18-20 08:51AM	Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7% Zacks
Sep-17-20 01:55PM	Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire +7.65%
Sep-14-20 06:55AM	Zynerba Pharmaceuticals Provides Update on Recent Milestones GlobeNewswire
Sep-10-20 07:30AM	Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire
Aug-10-20 06:45AM	Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights GlobeNewswire
Aug-06-20 07:00AM	Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-29-20 05:50PM	Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jul-24-20 10:16AM	What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-22-20 06:50AM	Zynerba Pharmaceuticals to Present an Update on the Zygel Development Program at the 17th NFXF International Fragile X Conference Research Roundup GlobeNewswire
Jul-05-20 02:00PM	The Week In Cannabis: Stocks Underperform Broader Market, Bad News For Zynerba, Organigram And More Benzinga
Jul-01-20 09:36AM	Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study Zacks +9.94%
Jun-30-20 07:57AM	Zynerba's cannabis-based drug for rare genetic disorder fails study Reuters -48.47%
07:41AM	The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test Benzinga
06:45AM	Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel (CBD Gel) in Fragile X Syndrome GlobeNewswire
Jun-29-20 08:57AM	Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options Zacks
Jun-25-20 11:26AM	Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba Zacks
Jun-17-20 09:43AM	3 Pharmaceutical Stocks With Major Catalysts Approaching TipRanks
Jun-15-20 08:53PM	Zynerba Pharmaceuticals Inc (ZYNE): Hedge Funds Are Nibbling Insider Monkey
May-27-20 06:45AM	Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder GlobeNewswire -9.69%
May-26-20 06:52AM	Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session GlobeNewswire
06:50AM	Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session GlobeNewswire
May-25-20 11:30AM	Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year? Zacks
May-22-20 07:30AM	Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +18.14%
May-21-20 08:00AM	Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic GlobeNewswire
May-11-20 06:50AM	Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights GlobeNewswire +11.53%
Apr-28-20 01:01PM	How Much is Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Getting Paid? Simply Wall St.
Apr-10-20 08:00AM	Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-02-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-25-20 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-10-20 06:50AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights GlobeNewswire +10.40%
Mar-09-20 08:30AM	Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting GlobeNewswire -13.93%
Mar-05-20 08:30AM	Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference GlobeNewswire
Mar-03-20 12:08PM	Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population GlobeNewswire
12:07PM	Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers GlobeNewswire
Mar-02-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-26-20 08:49AM	What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks -8.47%
06:50AM	Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome GlobeNewswire
Feb-25-20 11:21AM	Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To Profitability Simply Wall St. +7.13%

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience